Table 7.
Results of TP53 single nucleotide polymorphisms and risk of lung cancer from epidemiological studiesa.
| Lung cancerb | Reference | SNP | Location/PopulationC | Cases/Controls | Comparisond | OR (95% CI) | P valuee |
|---|---|---|---|---|---|---|---|
| LC | Sakiyama et al. [4] | rs1042522 | Japan/Hospital-based case-control | 1002/685 | CC vs. GG/SQC | 2.2 (1.3–3.9) | 0.005 |
| LC | Li et al. [5] | rs1042522 | China/Hospital-based case-control | 399/466 | CC vs. Any G | 1.57 (1.11–2.21) | – |
| rs2078486 | TC + CC vs. TT/Smoker | 1.70 (1.08–2.67) | – | ||||
| LC | Mostaid et al. [6] | rs1042522 | Bangladesh/Population-based case-control | 106/116 | GC or CC vs. GG | 2.51 (1.38–4.82)/4.62 (2.31–9.52) | – |
| LC | Mechanic et al. [7] | rs1042522 | USA/Hospital-based Case-control/AFA | 120/204 | Haplotype with C vs. G | 2.32 (1.18–4.57) | – |
| rs1042522C- rs9895829T- rs2909430A- rs1625895G- rs12951053G vs. G−T-A-G-T | |||||||
| LC | Popanda et al. [8] | rs1042522 | Genmany/Hospital-based case-control | 405/404 | SQC | ||
| CC+GC vs. GG | 1.65 (1.10–2.47) | 0.016 | |||||
| CC versus GG/HS | 2.80 (1.19–6.58) | 0.019 | |||||
| TP53 rs1042522CC+ CG/P21 rs1801270CC versus TP53 rs1042522GG/P21 rs1801270AA+AC | |||||||
| 3.84 (1.46–10.1) | 0.007 | ||||||
| ADC | Ren et al. [9] | rs1042522 | China/Hospital-based case-control/FNS | 764/983 | CC vs. GG | 1.55 (1.17–2.06) | 0.002 |
| Combination genotypes with CC | 2.66 (1.54–4.60) | <0.001 | |||||
| TP53 rs1042522CC+MDM2 rs2279744GG vs. TP53 rs1042522GG+MDM2 rs2279744TT | |||||||
| NSCLC | Yang et al. [10] | rs1042522 | China/Hospital-based case-control | 164/199 | Dominant model | 1.809 (1.159–2.825) | <0.05 |
| Recessive model | 1.933 (1.096–3.409) | <0.05 | |||||
| Combination genotypes with GG | 3.032 (1.580–5.816) | – | |||||
| SET8 rs16917496TT-TP53 rs1042522GG vs. CC+CT−CC+CG | |||||||
| LC | Myneni et al. [11] | rs1042522 | China//Population-based case-control | 399/466 | Diplotype with CC vs. GG+GC | 3.68 (1.43–9.45) | – |
| ATMrs227060TT–ATM rs228589AA-TP53 rs1042522CC vs. CC+CT−TT+TA−GG+GC | |||||||
| LC | Chua et al. [12] | rs1042522 | Singapore/Hospital-based case-control | 126/162 | Combination genotypes with C | 2.5 (1.2–5.0) | – |
| MDM2 rs2279744TT vs. TP53 rs1042522GC/CC +MDM2 rs2279744 GG/TG | |||||||
| LC | Mechanic et al. [7] | rs1042522 | USA/Hospital-based case-control/CA | 323/343 | AB or BB or AB+BB vs. AA: | 1.23 (0.86–1.76)/ | – |
| rs9895829 | 0.87 (0.41–1.84)/1.18 (0.84–1.66), 1.48 (0.78–2.82)/not determined/ | ||||||
| rs2909430 | 1.48 (0.78–2.82), 1.17 (0.77–1.78)/1.08 (0.31–3.76)/1.16 (0.77–1.74), | ||||||
| rs1625895 | 1.12 (0.74–1.68)/0.93 (0.25–3.41)/1.10 (0.74–1.64), 0.91 (0.56–1.49)/ | ||||||
| rs12951053 | 1.97 (0.19–20.6)/0.94 (0.58–1.52) | ||||||
| LC | Guan et al. [13] | rs78378222 | USA/Hospital-based case-control/NHW 1014/1076 | AC vs. AA | 0.84 (0.51–1.37) | 0.379 | |
| LC | Zhang et al. [14] | rs1042522 | China/Hospital-based case-control | 640/650 | CG or GG or CG+GG vs. CC | ||
| 1.02 (0.79–1.31) 0.882/0.99 (0.72–1.37) 0.963/1.1 (0.80–1.29) 0.924 | – | ||||||
| LC | Yin et al. [current] | rs1042522 | China/Hospital-based case-control | 544/550 | Haplotype with C vs. G | 0.13 (0.03–0.59) | 0.0079 |
| rs12951053 | rs12951053A-rs1042522C-rs8079544C-rs12602273G-rs8064946C vs. A−G-C-C-G | ||||||
| rs8079544 | Interaction of gene-gene-smoking duration | ||||||
| rs12602273 | Whole group: Three-way: TP53 rs8064946, CD3EAP rs967591, Smoking | ||||||
| rs8064946 | 0.006–0.007 | ||||||
| SQC group: Three-way: TP53 rs1042522, CD3EAP rs967591, Smoking | |||||||
| <0.001 | |||||||
a
Seeing Discussion for details.
b
LC: Lung cancer; ADC: Adenocarcinoma; NSCLC: Non-small-cell lung cancer.
c
AFA: African-American, FNS: Female non-smokers, CA: Caucasians Americans; NHW: Non-Hispanic Whites.
d
vs.: versus; SQC: Squamous cell carcinoma; HS: Heavy smokers; AB: Heterozygote; BB: Homozygous variant-type; AA: Homozygous wild-type.
e
-: Not reported.